chrysene - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	chrysene	go back to main search page
Accession:	CHEBI:51687	browse the term
Definition:	An ortho-fused polycyclic arene found commonly in the coal tar.
Synonyms:	related_synonym:	1,2,5,6-dibenzonaphthalene; 1,2-Benzophenanthrene; Benz[a]phenanthrene; Chrysen; Formula=C18H12; InChI=1S/C18H12/c1-3-7-15-13(5-1)9-11-18-16-8-4-2-6-14(16)10-12-17(15)18/h1-12H; InChIKey=WDECIBYCCFPHNR-UHFFFAOYSA-N; SMILES=c1ccc2c(c1)ccc1c3ccccc3ccc21; benzo[a]phenanthrene
	alt_id:	CHEBI:33087; CHEBI:34639
	xref:	Beilstein:1909297; CAS:218-01-9; Gmelin:262600; KEGG:C14222
	xref_mesh:	MESH:C031180
	xref:	MetaCyc:CPD-13772; PMID:24128549; PMID:24382467; PMID:24519633; Wikipedia:Chrysene

show annotations for term's descendants Sort by:
Rat (879) Mouse (949) Human (891) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (879)

chrysene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aladin WD repeat nucleoporin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AAAS mRNA

NCBI chr 7:133,464,315...133,483,961
Ensembl chr 7:133,464,315...133,483,961

G

ATP binding cassette subfamily B member 1A

increases expression

chrysene results in increased expression of ABCB1 mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 5

decreases expression
multiple interactions

chrysene results in decreased expression of ABCC5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABCC5 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ABI family member 3 binding protein

increases expression
multiple interactions

chrysene results in increased expression of ABI3BP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA

PMID:26377693 PMID:27858113

NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929

G

actin-binding LIM protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ABLIM1 mRNA

NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969

G

abraxas 2, BRISC complex subunit

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABRAXAS2 mRNA

NCBI chr 1:187,647,078...187,672,660
Ensembl chr 1:187,647,067...187,672,655

G

apoptotic chromatin condensation inducer 1

decreases expression
multiple interactions

chrysene results in decreased expression of ACIN1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACIN1 mRNA

PMID:26377693 PMID:27858113

NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001

G

aconitate decarboxylase 1

decreases expression

chrysene results in decreased expression of ACOD1 mRNA

NCBI chr15:79,871,819...79,881,101
Ensembl chr15:79,871,827...79,880,529

G

acyl-CoA thioesterase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA oxidase-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOXL mRNA

NCBI chr 3:115,061,069...115,367,032
Ensembl chr 3:115,061,060...115,364,686

G

actin, alpha 1, skeletal muscle

increases expression

chrysene results in increased expression of ACTA1 mRNA

NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742

G

actin alpha 2, smooth muscle

multiple interactions

[chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of ACTA2 protein; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actinin alpha 3

increases expression

chrysene results in increased expression of ACTN3 mRNA

NCBI chr 1:202,159,081...202,175,012
Ensembl chr 1:202,159,082...202,175,012

G

adenosine deaminase

increases expression

chrysene results in increased expression of ADA mRNA

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

ADAM metallopeptidase domain 33

increases expression

chrysene results in increased expression of ADAM33 mRNA

NCBI chr 3:118,262,395...118,283,456
Ensembl chr 3:118,271,029...118,283,461

G

ADAM-like, decysin 1

increases expression

chrysene results in increased expression of ADAMDEC1 mRNA

NCBI chr15:42,900,629...42,921,684
Ensembl chr15:42,900,636...42,921,712

G

ADAM metallopeptidase with thrombospondin type 1 motif, 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADAMTS14 mRNA

NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,144,354...29,219,866

G

adducin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADD3 mRNA

NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124

G

adhesion G protein-coupled receptor D1

increases expression

chrysene results in increased expression of ADGRD1 mRNA

NCBI chr12:27,488,908...27,603,714
Ensembl chr12:27,488,908...27,603,696

G

adhesion G protein-coupled receptor L4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADGRL4 mRNA

NCBI chr 2:240,354,909...240,457,231
Ensembl chr 2:240,354,941...240,457,225

G

adrenomedullin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

apoptosis enhancing nuclease

increases expression
multiple interactions

chrysene results in increased expression of AEN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AEN mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:132,815,094...132,824,522
Ensembl chr 1:132,815,142...132,824,523

G

AGBL carboxypeptidase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGBL2 mRNA

NCBI chr 3:76,764,893...76,800,071
Ensembl chr 3:76,764,238...76,800,214

G

argonaute RISC catalytic component 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGO2 mRNA

NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974

G

adenosylhomocysteinase-like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHCYL2 mRNA

NCBI chr 4:58,381,290...58,531,061
Ensembl chr 4:58,381,218...58,531,060

G

AHNAK nucleoprotein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHNAK mRNA

NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926

G

aryl hydrocarbon receptor

multiple interactions
affects response to substance
increases activity
affects binding

chrysene binds to and results in increased activity of AHR protein
AHR affects the susceptibility to chrysene
[benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [indeno(1,2,3-cd)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene] promotes the reaction [pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with pyrene] promotes the reaction [fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [chrysene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(k)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(j)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; [Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benz(a)anthracene results in increased activity of AHR protein]; [chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; alpha-naphthoflavone inhibits the reaction [[chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; chrysene binds to and results in increased activity of AHR protein; chrysene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]
chrysene binds to AHR protein
chrysene analog results in increased activity of AHR protein; chrysene results in increased activity of AHR protein

PMID:3024361 PMID:8571374 PMID:11525907 PMID:12371477 PMID:12799773 More...

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aryl-hydrocarbon receptor repressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AHRR mRNA

NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673

G

allograft inflammatory factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

A-kinase anchoring protein 12

increases expression

chrysene results in increased expression of AKAP12 mRNA

NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886

G

A-kinase anchoring protein 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AKAP7 mRNA

NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797

G

aldo-keto reductase family 1, member C1

increases expression

chrysene results in increased expression of AKR1C1 mRNA

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

ALG14, UDP-N-acetylglucosaminyltransferase subunit

decreases expression

chrysene results in decreased expression of ALG14 mRNA

NCBI chr 2:209,368,285...209,445,425
Ensembl chr 2:209,368,312...209,445,431

G

alkB homolog 7

decreases expression

chrysene results in decreased expression of ALKBH7 mRNA

NCBI chr 9:1,838,886...1,841,044
Ensembl chr 9:1,838,811...1,841,044

G

arachidonate epidermal lipoxygenase 3

increases expression

chrysene results in increased expression of ALOXE3 mRNA

NCBI chr10:53,830,219...53,854,328
Ensembl chr10:53,831,264...53,854,328

G

ALS2 C-terminal like

increases expression

chrysene results in increased expression of ALS2CL mRNA

NCBI chr 8:110,863,753...110,884,434
Ensembl chr 8:110,864,975...110,884,419

G

angiopoietin-like 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANK3 mRNA

NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300

G

ankyrin repeat domain 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANKRD12 mRNA

NCBI chr 9:105,583,273...105,687,957
Ensembl chr 9:105,584,065...105,687,911

G

ankyrin repeat domain containing 26

decreases expression

chrysene results in decreased expression of ANKRD26 mRNA

NCBI chr 4:151,670,604...151,740,032
Ensembl chr 4:151,672,037...151,739,968

G

alanyl aminopeptidase, membrane

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANPEP mRNA

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

adaptor related protein complex 1 subunit sigma 1

increases expression

chrysene results in increased expression of AP1S1 mRNA

NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713

G

apolipoprotein L9a

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of APOL9A mRNA

NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649

G

androgen receptor

multiple interactions
increases activity
decreases activity

chrysene binds to and results in decreased activity of AR protein; chrysene inhibits the reaction [Metribolone results in increased activity of AR protein]
chrysene results in increased activity of AR protein
chrysene results in decreased activity of AR protein

PMID:10771140 PMID:12799773 PMID:18324785

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

arginine and glutamate rich 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARGLU1 mRNA

NCBI chr16:80,753,300...80,777,350
Ensembl chr16:80,753,315...80,777,349

G

Rho GTPase activating protein 23

decreases expression

chrysene results in decreased expression of ARHGAP23 mRNA

NCBI chr10:82,437,578...82,496,846
Ensembl chr10:82,394,648...82,496,504

G

Rho guanine nucleotide exchange factor 38

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARHGEF38 mRNA

NCBI chr 2:221,610,212...221,739,841
Ensembl chr 2:221,613,070...221,740,079

G

Rho guanine nucleotide exchange factor 40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ARHGEF40 mRNA

NCBI chr15:24,672,645...24,696,510
Ensembl chr15:24,672,763...24,696,510

G

ARF like GTPase 3

decreases expression

chrysene results in decreased expression of ARL3 mRNA

NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820

G

armadillo repeat containing 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARMC6 mRNA

NCBI chr16:19,191,106...19,201,528
Ensembl chr16:19,191,093...19,206,047

G

arrestin domain containing 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA

NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290

G

asialoglycoprotein receptor 2

decreases expression
multiple interactions

chrysene results in decreased expression of ASGR2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASGR2 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:54,821,407...54,834,624
Ensembl chr10:54,821,438...54,834,617

G

aspartate-beta-hydroxylase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASPH mRNA

NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876

G

aspartic peptidase, retroviral-like 1

increases expression

chrysene results in increased expression of ASPRV1 mRNA

NCBI chr 4:119,077,415...119,078,887
Ensembl chr 4:119,077,356...119,078,379

G

activating transcription factor 4

increases expression

chrysene results in increased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

autophagy related 4C, cysteine peptidase

increases expression

chrysene results in increased expression of ATG4C mRNA

NCBI chr 5:113,867,218...113,935,534
Ensembl chr 5:113,867,092...113,934,830

G

ATPase 13A3

decreases expression
multiple interactions

chrysene results in decreased expression of ATP13A3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP13A3 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:70,364,998...70,442,005
Ensembl chr11:70,365,322...70,441,235

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP2A2 mRNA

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

ATP synthase membrane subunit G

decreases expression

chrysene results in decreased expression of ATP5MG mRNA

NCBI chr 8:45,225,680...45,233,630
Ensembl chr 8:45,225,686...45,233,559

G

ATPase H+ transporting V0 subunit a1

increases expression

chrysene results in increased expression of ATP6V0A1 mRNA

NCBI chr10:85,935,802...85,989,901
Ensembl chr10:85,935,854...85,989,895

G

ATPase H+ transporting V0 subunit a4

increases expression

chrysene results in increased expression of ATP6V0A4 mRNA

NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110

G

ATPase H+ transporting V0 subunit e1

decreases expression

chrysene results in decreased expression of ATP6V0E mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

ataxin 3

increases expression

chrysene results in increased expression of ATXN3 mRNA

NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902

G

beta-1,4-galactosyltransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of B4GALT1 mRNA

NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461

G

basic leucine zipper ATF-like transcription factor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BATF mRNA

NCBI chr 6:105,353,715...105,376,051
Ensembl chr 6:105,353,715...105,376,051

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BAX mRNA; [chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of BAX protein; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of BAX protein]

PMID:27858113 PMID:33345606

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

butyrylcholinesterase

increases expression

chrysene results in increased expression of BCHE mRNA

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

branched chain keto acid dehydrogenase E1 subunit beta

decreases expression

chrysene results in decreased expression of BCKDHB mRNA

NCBI chr 8:84,845,264...85,027,812
Ensembl chr 8:84,845,264...85,027,812

G

BCL11 transcription factor A

increases expression

chrysene results in increased expression of BCL11A mRNA

NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180

G

BCL2, apoptosis regulator

multiple interactions

[chrysene co-treated with Tobacco Smoke Pollution] results in decreased expression of BCL2 protein; chrysene promotes the reaction [Tobacco Smoke Pollution inhibits the reaction BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL3, transcription coactivator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

BCL6B, transcription repressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BCL6B mRNA

NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974

G

BAF chromatin remodeling complex subunit BCL7B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL7B mRNA

NCBI chr12:21,496,860...21,510,079
Ensembl chr12:21,496,856...21,510,202

G

BCL2-associated transcription factor 1

increases expression

chrysene results in increased expression of BCLAF1 mRNA

NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832

G

basic helix-loop-helix family, member e40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

baculoviral IAP repeat-containing 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

biogenesis of lysosomal organelles complex-1, subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BLOC1S2 mRNA

NCBI chr 1:243,024,611...243,031,749
Ensembl chr 1:243,024,614...243,031,653

G

basic helix-loop-helix ARNT like 1

decreases expression
multiple interactions

chrysene results in decreased expression of BMAL1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMAL1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

bone morphogenetic protein receptor type 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMPR2 mRNA

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

bromodomain containing 7

increases expression

chrysene results in increased expression of BRD7 mRNA

NCBI chr19:18,708,792...18,737,497
Ensembl chr19:18,709,022...18,737,494

G

BSCL2 lipid droplet biogenesis associated, seipin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA

NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421

G

B and T lymphocyte associated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BTLA mRNA

NCBI chr11:55,563,683...55,588,187
Ensembl chr11:55,564,899...55,587,181

G

C2 domain containing 3 centriole elongation regulator

decreases expression
multiple interactions

chrysene results in decreased expression of C2CD3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C2CD3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:154,715,151...154,812,955
Ensembl chr 1:154,715,310...154,812,520

G

complement C5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HC mRNA

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

complement C5a receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C5AR2 mRNA

NCBI chr 1:76,930,381...76,945,432
Ensembl chr 1:76,930,383...76,959,517

G

complement C7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C7 mRNA

NCBI chr 2:54,088,116...54,165,102
Ensembl chr 2:54,088,116...54,158,535

G

calcium binding protein 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CABP5 mRNA

NCBI chr 1:74,350,811...74,363,830
Ensembl chr 1:74,350,811...74,363,830

G

calcium voltage-gated channel auxiliary subunit gamma 1

increases expression

chrysene results in increased expression of CACNG1 mRNA

NCBI chr10:92,652,924...92,665,612
Ensembl chr10:92,652,614...92,665,783

G

calmodulin-like 5

increases expression

chrysene results in increased expression of CALM4 mRNA

NCBI chr17:66,394,433...66,395,352

G

calpain 3

increases expression

chrysene results in increased expression of CAPN3 mRNA

NCBI chr 3:107,407,518...107,457,858
Ensembl chr 3:107,407,850...107,457,858

G

capping actin protein of muscle Z-line subunit alpha 2

decreases expression

chrysene results in decreased expression of CAPZA2 mRNA

NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864

G

carbonic anhydrase 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAR14 mRNA

NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693

G

capping protein regulator and myosin 1 linker 1

decreases expression

chrysene results in decreased expression of CARMIL1 mRNA

NCBI chr17:40,807,921...41,088,326
Ensembl chr17:40,808,389...41,088,326

G

caspase 3

increases activity
multiple interactions

chrysene results in increased activity of CASP3 protein
chrysene promotes the reaction [Tobacco Smoke Pollution results in increased cleavage of CASP3 protein]

PMID:21571051 PMID:33345606

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

castor zinc finger 1

increases expression

chrysene results in increased expression of CASZ1 mRNA

NCBI chr 5:159,243,965...159,393,935
Ensembl chr 5:159,243,995...159,393,400

G

catalase

decreases activity

chrysene results in decreased activity of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

decreases expression
multiple interactions

chrysene results in decreased expression of CAV1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAV1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

caveolae associated protein 1

increases expression

chrysene results in increased expression of CAVIN1 mRNA

NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120

G

CBFA2/RUNX1 partner transcriptional co-repressor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CBFA2T3 mRNA

NCBI chr19:50,679,897...50,750,028
Ensembl chr19:50,680,729...50,749,610

G

collagen and calcium binding EGF domains 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCBE1 mRNA

NCBI chr18:59,579,851...59,823,977
Ensembl chr18:59,580,768...59,824,400

G

coiled-coil domain containing 184

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCDC184 mRNA

NCBI chr 7:129,297,635...129,301,961
Ensembl chr 7:129,298,212...129,304,494

G

coiled-coil domain containing 82

increases expression

chrysene results in increased expression of CCDC82 mRNA

NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963

G

C-C motif chemokine ligand 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 9

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCL6 mRNA

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

CCM2 like scaffold protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCM2L mRNA

NCBI chr 3:141,533,470...141,549,136
Ensembl chr 3:141,533,511...141,549,140

G

cyclin D1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin D1 binding protein 1

decreases expression

chrysene results in decreased expression of CCNDBP1 mRNA

NCBI chr 3:107,962,402...107,974,234
Ensembl chr 3:107,962,261...107,974,233

G

cyclin G1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

cyclin J-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNJL mRNA

NCBI chr10:27,995,682...28,053,428
Ensembl chr10:27,995,679...28,053,426

G

cyclin L1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNL1 mRNA

NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368

G

cyclin L2

increases expression

chrysene results in increased expression of CCNL2 mRNA

NCBI chr 5:166,416,940...166,428,997
Ensembl chr 5:166,417,508...166,436,882

G

C-C motif chemokine receptor 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCR7 mRNA

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

CD151 molecule (Raph blood group)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD151 mRNA

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

Cd200 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD200 mRNA

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648

G

CD248 molecule

increases expression

chrysene results in increased expression of CD248 mRNA

NCBI chr 1:202,373,676...202,376,240
Ensembl chr 1:202,373,676...202,376,240

G

CD34 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD34 mRNA

NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832

G

CD37 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD37 mRNA

NCBI chr 1:95,719,171...95,724,662
Ensembl chr 1:95,719,190...95,724,648

G

Cd47 molecule

decreases expression

chrysene results in decreased expression of CD47 mRNA

NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425

G

Cd48 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD48 mRNA

NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142

G

CD55 molecule (Cromer blood group)

increases expression

chrysene results in increased expression of CD55 mRNA

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

Cd69 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD69 mRNA

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

CD79b molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD79B mRNA

NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625

G

CD99 molecule (Xg blood group)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CD99 mRNA

NCBI chr20:54,418,239...54,422,882

G

cell division cycle 14B

increases expression

chrysene results in increased expression of CDC14B mRNA

NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235

G

cell division cycle 42

decreases expression

chrysene results in decreased expression of CDC42 mRNA

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cadherin 1

multiple interactions

[chrysene co-treated with Tobacco Smoke Pollution] results in decreased expression of CDH1 protein; chrysene promotes the reaction [Tobacco Smoke Pollution results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 13

increases expression

chrysene results in increased expression of CDH13 mRNA

NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459

G

cadherin 16

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDH16 mRNA

NCBI chr19:360,824...371,008
Ensembl chr19:360,824...371,007

G

cadherin 3

increases expression

chrysene results in increased expression of CDH3 mRNA

NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084

G

cadherin-related family member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDHR4 mRNA

NCBI chr 8:108,682,594...108,690,358
Ensembl chr 8:108,682,613...108,690,367

G

cyclin-dependent kinase 14

decreases expression

chrysene results in decreased expression of CDK14 mRNA

NCBI chr 4:28,666,416...29,258,865
Ensembl chr 4:28,666,843...29,258,861

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CCAAT/enhancer binding protein delta

decreases expression

chrysene results in decreased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

CUGBP, Elav-like family member 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CELF5 mRNA

NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,225,825...8,250,322

G

cadherin, EGF LAG seven-pass G-type receptor 2

increases expression

chrysene results in increased expression of CELSR2 mRNA

NCBI chr 2:196,029,206...196,053,848
Ensembl chr 2:196,029,434...196,053,845

G

centrosomal protein 162

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CEP162 mRNA

NCBI chr 8:88,149,726...88,208,249
Ensembl chr 8:88,149,726...88,206,830

G

centrosomal protein 41

decreases expression

chrysene results in decreased expression of CEP41 mRNA

NCBI chr 4:59,271,218...59,312,343
Ensembl chr 4:59,271,218...59,310,668

G

centrosomal protein 63

increases expression

chrysene results in increased expression of CEP63 mRNA

NCBI chr 8:103,162,639...103,214,177
Ensembl chr 8:103,162,700...103,214,177

G

carboxylesterase 2C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2C mRNA

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

carboxylesterase 2E

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2E mRNA
chrysene results in increased expression of CES2E mRNA

PMID:26377693 PMID:27858113

NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856

G

complement factor B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CFB mRNA

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

chromodomain helicase DNA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHD2 mRNA

NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502

G

chitinase, acidic

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CHIA mRNA

NCBI chr 2:193,614,374...193,656,532
Ensembl chr 2:193,614,114...193,656,533

G

choline kinase alpha

decreases expression

chrysene results in decreased expression of CHKA mRNA

NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516

G

carbohydrate sulfotransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHST1 mRNA

NCBI chr 3:78,552,059...78,574,740
Ensembl chr 3:78,548,525...78,574,883

G

cold inducible RNA binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CIRBP mRNA

NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818

G

cytokine inducible SH2-containing protein

decreases expression

chrysene results in decreased expression of CISH mRNA

NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CITED2 mRNA

NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897

G

cytoskeleton associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CKAP2 mRNA

NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913

G

CLK4-associating serine/arginine rich protein

increases expression

chrysene results in increased expression of SFRS16 mRNA

NCBI chr 1:79,232,260...79,256,462
Ensembl chr 1:79,232,261...79,256,354

G

C-type lectin domain family 1, member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC1A mRNA

NCBI chr 4:162,875,360...162,902,571
Ensembl chr 4:162,877,346...162,901,247

G

C-type lectin domain family 4, member A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC4A1 mRNA

NCBI chr 4:156,173,894...156,186,009
Ensembl chr 4:156,173,894...156,186,008

G

C-type lectin domain family 4, member F

decreases expression

chrysene results in decreased expression of CLEC4F mRNA

NCBI chr 4:116,129,023...116,138,744
Ensembl chr 4:116,129,023...116,138,775

G

C-type lectin domain family 4, member G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CLEC4G mRNA

NCBI chr12:1,780,370...1,785,027
Ensembl chr12:1,780,371...1,784,985

G

CDC-like kinase 4

increases expression

chrysene results in increased expression of CLK4 mRNA

NCBI chr10:35,523,382...35,541,387
Ensembl chr10:35,524,755...35,541,352

G

calsyntenin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA

NCBI chr 8:98,020,406...98,637,232
Ensembl chr 8:98,021,666...98,637,731

G

cytidine/uridine monophosphate kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CMPK2 mRNA

NCBI chr 6:43,073,706...43,085,183
Ensembl chr 6:43,073,796...43,085,183

G

cordon-bleu WH2 repeat protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COBL mRNA

NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800

G

collagen type XVII alpha 1 chain

increases expression

chrysene results in increased expression of COL17A1 mRNA

NCBI chr 1:246,530,589...246,577,559
Ensembl chr 1:246,531,367...246,577,632

G

collagen type I alpha 1 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type XX alpha 1 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COL20A1 mRNA

NCBI chr 3:168,102,475...168,134,759
Ensembl chr 3:168,084,560...168,135,309

G

collagen type III alpha 1 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL3A1 mRNA; [chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of COL3A1 protein; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of COL3A1 protein]

PMID:27858113 PMID:33345606

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type IV alpha 4 chain

decreases expression
multiple interactions

chrysene results in decreased expression of COL4A4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL4A4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:83,833,173...83,875,436
Ensembl chr 9:83,755,515...83,875,876

G

collagen type IV alpha 6 chain

increases expression

chrysene results in increased expression of COL4A6 mRNA

NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500

G

collagen type V alpha 3 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL5A3 mRNA

NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853

G

COMM domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COMMD3 mRNA

NCBI chr17:81,327,444...81,331,191
Ensembl chr17:81,327,405...81,331,177

G

COPI coat complex subunit epsilon

decreases expression

chrysene results in decreased expression of COPE mRNA

NCBI chr16:19,114,871...19,125,076
Ensembl chr16:19,114,871...19,128,907

G

coordinator of PRMT5 and differentiation stimulator

decreases expression

chrysene results in decreased expression of COPRS mRNA

NCBI chr16:75,721,264...75,726,375
Ensembl chr16:75,720,061...75,726,375

G

coenzyme Q10B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ10B mRNA

NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663

G

coenzyme Q8A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ8A mRNA

NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431

G

coronin 2A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CORO2A mRNA

NCBI chr 5:60,825,630...60,881,917
Ensembl chr 5:60,828,247...60,859,035

G

complexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPLX2 mRNA

NCBI chr17:10,219,577...10,292,835
Ensembl chr17:10,222,347...10,293,855

G

copine 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPNE4 mRNA

NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:105,177,376...105,653,068

G

copine 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPNE5 mRNA

NCBI chr20:7,206,742...7,289,309
Ensembl chr20:7,206,742...7,288,883

G

carnitine palmitoyltransferase 1c

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPT1C mRNA

NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342

G

carboxypeptidase X (M14 family), member 2

increases expression

chrysene results in increased expression of CPXM2 mRNA

NCBI chr 1:186,836,797...186,947,222
Ensembl chr 1:186,836,797...186,947,220

G

complement C3d receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CR2 mRNA

NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235

G

cysteine-rich C-terminal 1

increases expression

chrysene results in increased expression of CRCT1 mRNA

NCBI chr 2:178,633,789...178,635,274
Ensembl chr 2:178,634,092...178,634,394

G

cysteine-rich secretory protein LCCL domain containing 2

increases expression

chrysene results in increased expression of CRISPLD2 mRNA

NCBI chr19:48,053,153...48,111,485
Ensembl chr19:48,053,287...48,110,465

G

CRK proto-oncogene, adaptor protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CRK mRNA

NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406

G

casein kinase 1, gamma 2

increases expression

chrysene results in increased expression of CSNK1G2 mRNA

NCBI chr 7:9,076,739...9,095,082
Ensembl chr 7:9,076,740...9,095,052

G

cystatin 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CST8 mRNA

NCBI chr 3:136,244,586...136,255,412
Ensembl chr 3:136,244,636...136,251,273

G

C-X-C motif chemokine ligand 13

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCL13 mRNA

NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933

G

C-X-C motif chemokine receptor 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CXCR5 mRNA

NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893

G

C-X-C motif chemokine receptor 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCR6 mRNA

NCBI chr 8:123,434,417...123,439,568
Ensembl chr 8:123,416,325...123,439,526

G

CYLD lysine 63 deubiquitinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA

NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYP17A1 mRNA

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity
decreases expression

[benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1A1 mRNA; [benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1A1 protein; [chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; alpha-naphthoflavone inhibits the reaction [[chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; chrysene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of chrysene]
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1A1 mRNA; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of chrysene]
[chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA; [chrysene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA; chrysene inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
chrysene results in increased expression of CYP1A1 mRNA; chrysene results in increased expression of CYP1A1 protein
chrysene results in increased activity of CYP1A1 protein
chrysene results in decreased expression of CYP1A1 mRNA

PMID:7750161 PMID:8961944 PMID:10190573 PMID:12107646 PMID:12117779 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

[CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of chrysene]
[CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of chrysene]
chrysene results in increased expression of CYP1A2 mRNA
[chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A2 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A2 mRNA; [chrysene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA

PMID:7750161 PMID:8961944 PMID:12107646 PMID:17253728 PMID:31087746 More...

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
increases expression

[benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]]; [chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1B1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1B1 mRNA; [chrysene co-treated with Benzo(a)pyrene] results in increased expression of CYP1B1 mRNA; chrysene inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]
chrysene results in increased expression of CYP1B1 mRNA
chrysene results in increased expression of CYP1B1 mRNA; chrysene results in increased expression of CYP1B1 protein
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1B1 mRNA
[benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1B1 mRNA; [benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of CYP1B1 protein

PMID:12107646 PMID:12117779 PMID:15315710 PMID:15566942 PMID:17253728 More...

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

chrysene results in increased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cystin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYS1 mRNA

NCBI chr 6:41,300,836...41,318,071
Ensembl chr 6:41,300,836...41,318,071

G

cysteine rich tail 1

increases expression

chrysene results in increased expression of CYSRT1 mRNA

NCBI chr 3:8,054,195...8,057,846
Ensembl chr 3:8,053,482...8,059,721

G

differentiation antagonizing non-protein coding RNA

increases expression

chrysene results in increased expression of DANCR mRNA

NCBI chr14:34,126,956...34,127,936

G

aspartyl-tRNA synthetase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DARS1 mRNA

NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116

G

D-box binding PAR bZIP transcription factor

increases expression
multiple interactions

chrysene results in increased expression of DBP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DBP mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745

G

DDB1 and CUL4 associated factor 12-like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCAF12L2 mRNA

NCBI chr X:123,293,761...123,296,550
Ensembl chr X:123,294,744...123,296,156

G

DDB1 and CUL4 associated factor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DCAF4 mRNA

NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982

G

DCC netrin 1 receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCC mRNA

NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740

G

decorin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCN mRNA

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

dimethylarginine dimethylaminohydrolase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDAH1 mRNA

NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339

G

dopa decarboxylase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDC mRNA

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

DNA damage-induced apoptosis suppressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIAS mRNA

NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462

G

DNA-damage-inducible transcript 4-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIT4L mRNA

NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375

G

DEAD-box helicase 25

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX25 mRNA

NCBI chr 8:33,894,224...33,910,377
Ensembl chr 8:33,894,232...33,921,764

G

DEAD-box helicase 5

increases expression
multiple interactions

chrysene results in increased expression of DDX5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX5 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283

G

DEF6 guanine nucleotide exchange factor

increases expression

chrysene results in increased expression of DEF6 mRNA

NCBI chr20:6,268,579...6,290,030
Ensembl chr20:6,268,601...6,289,961

G

diacylglycerol O-acyltransferase 2

increases expression
multiple interactions

chrysene results in increased expression of DGAT2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DGAT2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428

G

diacylglycerol kinase, alpha

increases expression

chrysene results in increased expression of DGKA mRNA

NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110

G

diacylglycerol kinase, theta

increases expression

chrysene results in increased expression of DGKQ mRNA

NCBI chr14:1,059,125...1,073,131
Ensembl chr14:1,059,170...1,073,131

G

diaphanous-related formin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIAP1 mRNA

NCBI chr18:29,669,659...29,769,070
Ensembl chr18:29,669,659...29,769,172

G

dicer 1 ribonuclease III

increases expression

chrysene results in increased expression of DICER1 mRNA

NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965

G

death inducer-obliterator 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIDO1 mRNA

NCBI chr 3:167,772,535...167,825,894
Ensembl chr 3:167,772,770...167,817,218

G

divergent protein kinase domain 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DIPK1B mRNA

NCBI chr 3:9,455,914...9,464,169
Ensembl chr 3:9,456,409...9,464,161

G

DIX domain containing 1

decreases expression

chrysene results in decreased expression of DIXDC1 mRNA

NCBI chr 8:51,007,835...51,081,191
Ensembl chr 8:51,007,838...51,081,090

G

cyclin D binding myb-like transcription factor 1

decreases expression

chrysene results in decreased expression of DMTF1 mRNA

NCBI chr 4:24,909,937...24,950,786
Ensembl chr 4:24,910,534...24,950,967

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJA1 mRNA

NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJB4 mRNA

NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089

G

DnaJ heat shock protein family (Hsp40) member B5

increases expression

chrysene results in increased expression of DNAJB5 mRNA

NCBI chr 5:57,176,840...57,186,067
Ensembl chr 5:57,176,845...57,185,490

G

DnaJ heat shock protein family (Hsp40) member C8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DNAJC8 mRNA

NCBI chr 5:144,745,055...144,763,106
Ensembl chr 5:144,745,036...144,763,108

G

dynamin 2

increases expression

chrysene results in increased expression of DNM2 mRNA

NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157

G

dolichyldiphosphatase 1

increases expression

chrysene results in increased expression of DOLPP1 mRNA

NCBI chr 3:13,666,000...13,674,312
Ensembl chr 3:13,665,823...13,674,311

G

denticleless E3 ubiquitin protein ligase homolog

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DTL mRNA

NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890

G

deltex E3 ubiquitin ligase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DTX4 mRNA

NCBI chr 1:209,457,719...209,545,163
Ensembl chr 1:209,460,735...209,492,818

G

dual specificity phosphatase 3

decreases expression

chrysene results in decreased expression of DUSP3 mRNA

NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962

G

dishevelled segment polarity protein 3

decreases expression
multiple interactions

chrysene results in decreased expression of DVL3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DVL3 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462

G

DAZ interacting zinc finger protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DZIP1 mRNA

NCBI chr15:95,956,329...96,009,994
Ensembl chr15:95,956,398...96,010,066

G

extracellular matrix protein 1

increases expression
multiple interactions

chrysene results in increased expression of ECM1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ECM1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:183,287,491...183,292,729
Ensembl chr 2:183,287,322...183,292,671

G

endothelin receptor type B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

EF-hand domain family, member D1

increases expression

chrysene results in increased expression of EFHD1 mRNA

NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917

G

ephrin A1

increases expression

chrysene results in increased expression of EFNA1 mRNA

NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866

G

ephrin B1

decreases expression
multiple interactions

chrysene results in decreased expression of EFNB1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EFNB1 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:64,257,351...64,270,158
Ensembl chr X:64,257,351...64,270,157

G

embryonal Fyn-associated substrate

increases expression

chrysene results in increased expression of EFS mRNA

NCBI chr15:28,392,417...28,403,016
Ensembl chr15:28,392,187...28,401,902

G

EH domain binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EHBP1 mRNA

NCBI chr14:96,093,327...96,380,502
Ensembl chr14:96,093,327...96,345,332

G

EH-domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD1 mRNA

NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212

G

EH-domain containing 4

increases expression
multiple interactions

chrysene results in increased expression of EHD4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002

G

eukaryotic translation initiation factor 1

increases expression

chrysene results in increased expression of EIF1 mRNA

NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
Ensembl chr 5:85,246,764...85,427,327

G

eukaryotic translation initiation factor 3, subunit D

increases expression

chrysene results in increased expression of EIF3D mRNA

NCBI chr 7:109,539,795...109,552,184
Ensembl chr 7:109,539,356...109,552,206

G

eukaryotic translation initiation factor 4E binding protein 3

increases expression

chrysene results in increased expression of EIF4EBP3 mRNA

NCBI chr18:28,263,089...28,268,033
Ensembl chr18:28,162,311...28,268,024

G

eukaryotic translation initiation factor 4 gamma 1

increases expression

chrysene results in increased expression of EIF4G1 mRNA

NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941

G

eukaryotic translation initiation factor 4 gamma, 3

increases expression

chrysene results in increased expression of EIF4G3 mRNA

NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363

G

endomucin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EMCN mRNA

NCBI chr 2:225,891,100...225,970,932
Ensembl chr 2:225,891,100...225,970,929

G

EMAP like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EML1 mRNA

NCBI chr 6:127,283,968...127,457,246
Ensembl chr 6:127,284,029...127,457,246

G

erythrocyte membrane protein band 4.1

decreases expression
multiple interactions

chrysene results in decreased expression of EPB41 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:144,110,010...144,264,037
Ensembl chr 5:144,111,906...144,237,821

G

Eph receptor A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHA1 mRNA

NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846

G

epoxide hydrolase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHX1 mRNA; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of chrysene]; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of chrysene]

PMID:8961944 PMID:27858113

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

erythropoietin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPOR mRNA

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

ermin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ERMN mRNA

NCBI chr 3:42,628,160...42,633,816
Ensembl chr 3:42,626,309...42,633,744

G

estrogen receptor 1

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with chrysene] results in increased expression of ESR1 mRNA
chrysene results in increased expression of ESR1 mRNA

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

EWS RNA-binding protein 1

decreases expression

chrysene results in decreased expression of EWSR1 mRNA

NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544

G

exocyst complex component 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EXOC4 mRNA

NCBI chr 4:61,807,706...62,584,316
Ensembl chr 4:61,807,761...62,585,723

G

exocyst complex component 6B

increases expression

chrysene results in increased expression of EXOC6B mRNA

NCBI chr 4:117,094,741...117,550,221
Ensembl chr 4:117,094,741...117,550,180

G

coagulation factor XIII A1 chain

increases expression

chrysene results in increased expression of F13A1 mRNA

NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700

G

coagulation factor V

increases expression

chrysene results in increased expression of F5 mRNA

NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317

G

family with sequence similarity 107, member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FAM107A mRNA

NCBI chr15:16,608,362...16,630,398
Ensembl chr15:16,607,205...16,630,396

G

family with sequence similarity 110, member D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM110D mRNA

NCBI chr 5:146,471,048...146,474,019
Ensembl chr 5:146,471,049...146,474,056

G

family with sequence similarity 133, member B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM133B mRNA

NCBI chr 4:30,589,646...30,616,291
Ensembl chr 4:30,589,635...30,616,040

G

family with sequence similarity 13, member C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM13C mRNA

NCBI chr20:18,065,625...18,187,792
Ensembl chr20:18,065,628...18,187,592

G

FAM20B, glycosaminoglycan xylosylkinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM20B mRNA

NCBI chr13:68,801,663...68,839,979
Ensembl chr13:68,801,669...68,839,915

G

FERM, ARH/RhoGEF and pleckstrin domain protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FARP1 mRNA

NCBI chr15:98,124,304...98,363,299
Ensembl chr15:98,182,329...98,363,299

G

Fas-activated serine/threonine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FASTK mRNA

NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430

G

FAT atypical cadherin 2

increases expression

chrysene results in increased expression of FAT2 mRNA

NCBI chr10:39,364,072...39,456,324
Ensembl chr10:39,364,073...39,456,216

G

F-box protein 2

decreases expression

chrysene results in decreased expression of FBXO2 mRNA

NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355

G

Fc epsilon receptor II

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FCER2A mRNA

NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476

G

ferredoxin-fold anticodon binding domain containing 1

increases expression

chrysene results in increased expression of FDXACB1 mRNA

NCBI chr 8:51,111,831...51,118,253
Ensembl chr 8:51,113,397...51,118,308

G

fibroblast growth factor 9

increases expression

chrysene results in increased expression of FGF9 mRNA

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

FGFR1 oncogene partner 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FGFR1OP2 mRNA

NCBI chr 4:179,491,602...179,512,630
Ensembl chr 4:179,491,599...179,512,630

G

fibroblast growth factor receptor 3

increases expression

chrysene results in increased expression of FGFR3 mRNA

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

forkhead associated phosphopeptide binding domain 1

increases expression

chrysene results in increased expression of FHAD1 mRNA

NCBI chr 5:154,191,593...154,310,442
Ensembl chr 5:154,191,745...154,310,354

G

fin bud initiation factor homolog

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FIBIN mRNA

NCBI chr 3:96,942,405...96,944,676
Ensembl chr 3:96,942,406...96,944,676

G

FIG4 phosphoinositide 5-phosphatase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIG4 mRNA

NCBI chr20:44,600,603...44,724,047
Ensembl chr20:44,600,603...44,723,844

G

fidgetin-like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA

NCBI chr14:86,368,670...86,381,728
Ensembl chr14:86,368,675...86,377,455

G

FKBP prolyl isomerase 1A

decreases expression
multiple interactions

chrysene results in decreased expression of FKBP1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FKBP1A mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743

G

FKBP prolyl isomerase 3

increases expression

chrysene results in increased expression of FKBP3 mRNA

NCBI chr 6:83,113,885...83,125,500
Ensembl chr 6:83,113,786...83,127,011

G

FLII, actin remodeling protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FLII mRNA

NCBI chr10:45,394,032...45,408,051
Ensembl chr10:45,394,032...45,407,970

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

fragile X messenger ribonucleoprotein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA

NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050

G

fibronectin type III domain containing 1

increases expression
multiple interactions

chrysene results in increased expression of FNDC1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FNDC1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:47,281,839...47,364,247
Ensembl chr 1:47,281,844...47,364,259

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

chrysene results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box F1

increases expression
multiple interactions

chrysene results in increased expression of FOXF1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FOXF1 mRNA

PMID:26377693 PMID:27858113

NCBI chr19:49,153,949...49,157,741
Ensembl chr19:49,153,699...49,157,738

G

forkhead box S1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FOXS1 mRNA

NCBI chr 3:141,397,012...141,398,296
Ensembl chr 3:141,397,016...141,398,281

G

FSHD region gene 1

decreases expression
multiple interactions

chrysene results in decreased expression of FRG1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRG1 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:50,925,783...50,946,661
Ensembl chr16:50,925,803...50,946,661

G

FERM domain containing 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRMD4B mRNA

NCBI chr 4:129,895,401...130,222,070
Ensembl chr 4:129,895,708...130,084,197

G

fascin actin-bundling protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FSCN3 mRNA

NCBI chr 4:57,042,797...57,052,224
Ensembl chr 4:57,042,797...57,052,404

G

FMR1 autosomal homolog 2

increases expression

chrysene results in increased expression of FXR2 mRNA

NCBI chr10:54,350,577...54,370,964
Ensembl chr10:54,350,131...54,370,964

G

FXYD domain-containing ion transport regulator 3

increases expression

chrysene results in increased expression of FXYD3 mRNA

NCBI chr 1:86,305,531...86,312,455

G

gamma-aminobutyric acid type A receptor subunit alpha 3

increases expression

chrysene results in increased expression of GABRA3 mRNA

NCBI chr X:150,244,745...150,501,566
Ensembl chr X:150,261,607...150,501,559

G

growth arrest specific 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GAS6 mRNA

NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904

G

golgi associated kinase 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GASK1B mRNA

NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GATA2 mRNA

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

GATA zinc finger domain containing 2A

increases expression

chrysene results in increased expression of GATAD2A mRNA

NCBI chr16:19,429,578...19,520,320
Ensembl chr16:19,429,578...19,519,587

G

glucagon receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GCGR mRNA

NCBI chr10:105,808,474...105,816,641
Ensembl chr10:105,808,473...105,816,640

G

GTP cyclohydrolase 1

decreases expression

chrysene results in decreased expression of GCH1 mRNA

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

glial cells missing transcription factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GCM1 mRNA

NCBI chr 8:78,925,687...78,938,924
Ensembl chr 8:78,925,687...78,938,924

G

GCN1 activator of EIF2AK4

increases expression

chrysene results in increased expression of GCN1 mRNA

NCBI chr12:40,991,512...41,052,661
Ensembl chr12:40,991,512...41,052,555

G

guanine deaminase

increases expression

chrysene results in increased expression of GDA mRNA

NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416

G

growth differentiation factor 15

decreases expression
multiple interactions

chrysene results in decreased expression of GDF15 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GDF15 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

GDNF family receptor alpha 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GFRA4 mRNA

NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329

G

gap junction protein, beta 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GJB1 mRNA

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

GLIS family zinc finger 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GLIS2 mRNA

NCBI chr10:10,951,157...10,978,524
Ensembl chr10:10,951,371...10,971,578

G

geminin, DNA replication inhibitor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GMNN mRNA

NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054

G

G protein subunit alpha i1

increases expression

chrysene results in increased expression of GNAI1 mRNA

NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417

G

G patch domain containing 1

affects expression

chrysene affects the expression of GPATCH1 mRNA

NCBI chr 1:87,925,606...87,974,544
Ensembl chr 1:87,925,618...87,974,544

G

glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPIHBP1 mRNA

NCBI chr 7:107,285,584...107,288,702
Ensembl chr 7:107,285,654...107,288,702

G

G protein-coupled receptor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GPR4 mRNA

NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599

G

GPRIN family member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPRIN3 mRNA

NCBI chr 4:88,572,062...88,657,369
Ensembl chr 4:88,563,607...88,657,429

G

growth factor receptor bound protein 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRB10 mRNA

NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806

G

growth regulating estrogen receptor binding 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GREB1 mRNA

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

galectin-related inter-fiber protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRIFIN mRNA

NCBI chr12:14,080,170...14,082,892
Ensembl chr12:14,080,910...14,082,877

G

GRIP1 associated protein 1

increases expression

chrysene results in increased expression of GRIPAP1 mRNA

NCBI chr X:14,678,896...14,708,747
Ensembl chr X:14,678,898...14,708,679

G

gastrin releasing peptide

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRP mRNA

NCBI chr18:59,388,679...59,402,061
Ensembl chr18:59,388,274...59,402,061

G

glutathione S-transferase mu 1

multiple interactions

GSTM1 protein affects the metabolism of [chrysene co-treated with Glutathione]

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

general transcription factor IIIC subunit 1

increases expression

chrysene results in increased expression of GTF3C1 mRNA

NCBI chr 1:180,203,995...180,270,201
Ensembl chr 1:180,203,995...180,270,201

G

granzyme A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GZMA mRNA

NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493

G

H19 imprinted maternally expressed transcript

increases expression

chrysene results in increased expression of H19 mRNA

NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134

G

H1.1 linker histone, cluster member

decreases expression

chrysene results in decreased expression of H1F1 mRNA

NCBI chr17:41,366,268...41,367,011
Ensembl chr17:41,366,268...41,367,011

G

H1.2 linker histone, cluster member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H1F2 mRNA

NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635

G

H1.4 linker histone, cluster member

decreases expression
multiple interactions

chrysene results in decreased expression of H1F4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H1F4 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:41,486,574...41,487,355
Ensembl chr17:41,486,560...41,487,403

G

hydroxyacyl glutathione hydrolase

decreases expression

chrysene results in decreased expression of HAGH mRNA

NCBI chr10:13,874,883...13,889,527
Ensembl chr10:13,875,241...13,889,504

G

HEAT repeat containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HEATR1 mRNA

NCBI chr17:58,053,288...58,093,895
Ensembl chr17:58,051,700...58,093,948

G

HECT and RLD domain containing E3 ubiquitin protein ligase 4

increases expression

chrysene results in increased expression of HERC4 mRNA

NCBI chr20:25,329,972...25,404,657
Ensembl chr20:25,330,280...25,404,657

G

HIC ZBTB transcriptional repressor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HIC1 mRNA

NCBI chr10:60,014,520...60,019,475
Ensembl chr10:60,011,528...60,019,475

G

hypoxia inducible lipid droplet-associated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HILPDA mRNA

NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557

G

HLF transcription factor, PAR bZIP family member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HLF mRNA

NCBI chr10:75,154,244...75,211,884
Ensembl chr10:75,154,507...75,211,935

G

histocompatibility minor 13

decreases expression
multiple interactions

chrysene results in decreased expression of H13 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H13 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:141,145,792...141,183,557
Ensembl chr 3:141,145,782...141,184,703

G

homeobox containing 1

decreases expression

chrysene results in decreased expression of HMBOX1 mRNA

NCBI chr15:39,067,805...39,200,633
Ensembl chr15:39,067,804...39,200,323

G

hemicentin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMCN1 mRNA

NCBI chr13:62,615,461...63,084,524
Ensembl chr13:62,615,461...63,084,524

G

hemicentin 2

increases expression

chrysene results in increased expression of HMCN2 mRNA

NCBI chr 3:14,588,353...14,738,320
Ensembl chr 3:14,588,662...14,738,025

G

high mobility group box 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGB1 mRNA

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group nucleosome binding domain 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGN5 mRNA

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441
Ensembl chr 1:74,085,875...74,094,441

G

hyaluronan-mediated motility receptor

decreases expression

chrysene results in decreased expression of HMMR mRNA

NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060

G

heterogeneous nuclear ribonucleoprotein A/B

increases expression

chrysene results in increased expression of HNRNPAB mRNA

NCBI chr10:35,857,040...35,862,935
Ensembl chr10:35,857,041...35,863,344

G

heterogeneous nuclear ribonucleoprotein F

increases expression
multiple interactions

chrysene results in increased expression of HNRNPF mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HNRNPF mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:151,083,262...151,104,464
Ensembl chr 4:151,083,062...151,109,038

G

heterogeneous nuclear ribonucleoprotein H1

increases expression

chrysene results in increased expression of HNRNPH1 mRNA

NCBI chr10:34,692,868...34,702,849
Ensembl chr10:34,693,555...34,702,846

G

HPS1, biogenesis of lysosomal organelles complex 3 subunit 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HPS1 mRNA

NCBI chr 1:241,551,180...241,577,292
Ensembl chr 1:241,551,175...241,577,268

G

HR, lysine demethylase and nuclear receptor corepressor

increases expression

chrysene results in increased expression of HR mRNA

NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313

G

hydroxysteroid (17-beta) dehydrogenase 14

increases expression

chrysene results in increased expression of HSD17B14 mRNA

NCBI chr 1:96,029,224...96,039,577
Ensembl chr 1:96,029,284...96,039,883

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

HIV-1 Tat interactive protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HTATIP2 mRNA

NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629

G

HIV-1 Tat specific factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HTATSF1 mRNA

NCBI chr X:134,935,426...134,949,607
Ensembl chr X:134,935,426...134,949,607

G

hormonally upregulated Neu-associated kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HUNK mRNA

NCBI chr11:29,641,122...29,758,392
Ensembl chr11:29,640,775...29,757,526

G

islet cell autoantigen 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ICA1 mRNA

NCBI chr 4:36,656,475...36,804,705
Ensembl chr 4:36,656,475...36,804,298

G

intercellular adhesion molecule 1

increases expression

chrysene results in increased expression of ICAM1 protein

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inducible T-cell co-stimulator ligand

increases expression

chrysene results in increased expression of ICOSL mRNA

NCBI chr20:10,600,420...10,610,718
Ensembl chr20:10,600,420...10,610,703

G

inhibitor of DNA binding 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

immediate early response 3

increases expression

chrysene results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

immediate early response 5

decreases expression
multiple interactions

chrysene results in decreased expression of IER5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IER5 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227

G

immunoglobulin superfamily, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IGSF3 mRNA

NCBI chr 2:188,811,394...188,899,645
Ensembl chr 2:188,811,380...188,899,645

G

IK cytokine

increases expression

chrysene results in increased expression of IK mRNA

NCBI chr18:28,358,004...28,372,809
Ensembl chr18:28,357,977...28,378,832

G

IKAROS family zinc finger 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IKZF4 mRNA

NCBI chr 7:1,063,283...1,102,940
Ensembl chr 7:1,056,890...1,084,341

G

interleukin 10

multiple interactions

[chrysene co-treated with Tobacco Smoke Pollution] results in decreased expression of IL10 mRNA; [chrysene co-treated with Tobacco Smoke Pollution] results in decreased expression of IL10 protein; chrysene promotes the reaction [Tobacco Smoke Pollution results in decreased expression of IL10 mRNA]; chrysene promotes the reaction [Tobacco Smoke Pollution results in decreased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 17A

multiple interactions

[chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of IL17A mRNA; [chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of IL17A protein; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL17A mRNA]; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL17A protein]

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 17F

multiple interactions

[chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of IL17F mRNA; [chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of IL17F protein; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL17F mRNA]; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL17F protein]

NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482

G

interleukin 18 receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IL18R1 mRNA

NCBI chr 9:42,727,416...42,760,971
Ensembl chr 9:42,727,869...42,760,715

G

interleukin 1 beta

multiple interactions

[chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of IL1B mRNA; [chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of IL1B protein; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL1B mRNA]; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases expression
multiple interactions

chrysene results in increased expression of IL6 mRNA
[chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of IL6 mRNA; [chrysene co-treated with Tobacco Smoke Pollution] results in increased expression of IL6 protein; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL6 mRNA]; chrysene promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL6 protein]

PMID:25433334 PMID:33345606

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin enhancer binding factor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILF2 mRNA

NCBI chr 2:175,952,174...175,971,191
Ensembl chr 2:175,952,186...175,971,337

G

inflammation and lipid regulator with UBA-like and NBR1-like domains

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILRUN mRNA

NCBI chr20:5,809,931...5,876,197
Ensembl chr20:5,809,936...5,876,012

G

inka box actin regulator 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of INKA2 mRNA

NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:193,185,275...193,200,642

G

INO80 complex subunit B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of INO80B mRNA

NCBI chr 4:115,627,907...115,631,069
Ensembl chr 4:115,627,908...115,631,456

G

IQ motif and Sec7 domain ArfGEF 1

decreases expression

chrysene results in decreased expression of IQSEC1 mRNA

NCBI chr 4:123,168,719...123,488,300
Ensembl chr 4:123,168,719...123,488,172

G

inositol 1,4,5-triphosphate receptor associated 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IRAG2 mRNA

NCBI chr 4:178,088,902...178,143,569
Ensembl chr 4:178,088,507...178,143,557

G

interferon regulatory factor 2 binding protein-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IRF2BPL mRNA

NCBI chr 6:106,527,179...106,531,294
Ensembl chr 6:106,528,053...106,530,401

G

integrin subunit alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA1 mRNA

NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238

G

integrin subunit alpha 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA7 mRNA

NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450

G

integrin subunit alpha X

decreases expression

chrysene results in decreased expression of ITGAX mRNA

NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698

G

integrin subunit beta 1

decreases expression

chrysene results in decreased expression of ITGB1 mRNA

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

inter-alpha-trypsin inhibitor heavy chain 5

increases expression

chrysene results in increased expression of ITIH5 mRNA

NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207

G

inositol 1,4,5-trisphosphate receptor, type 2

increases expression

chrysene results in increased expression of ITPR2 mRNA

NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

chrysene results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

increases expression

chrysene results in increased expression of JUNB mRNA

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

KN motif and ankyrin repeat domains 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KANK4 mRNA

NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555

G

lysine acetyltransferase 14

increases expression

chrysene results in increased expression of KAT14 mRNA

NCBI chr 3:131,736,430...131,781,732
Ensembl chr 3:131,736,549...131,781,706

G

potassium voltage-gated channel subfamily E regulatory subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA

NCBI chr 1:154,523,903...154,530,865
Ensembl chr 1:154,523,830...154,532,020

G

potassium channel tetramerization domain containing 15

increases expression

chrysene results in increased expression of KCTD15 mRNA

NCBI chr 1:87,258,658...87,271,979
Ensembl chr 1:87,258,658...87,273,497

G

KIAA0232 homolog

increases expression

chrysene results in increased expression of D5ERTD579E mRNA

NCBI chr14:74,094,421...74,159,316
Ensembl chr14:74,094,488...74,159,326

G

kinesin family member 26B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KIF26B mRNA

NCBI chr13:90,282,821...90,689,058
Ensembl chr13:90,283,404...90,682,811

G

KIT ligand

decreases expression
multiple interactions

chrysene results in decreased expression of KITL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KITL mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

kelch-like family member 18

increases expression

chrysene results in increased expression of KLHL18 mRNA

NCBI chr 8:110,400,679...110,459,442
Ensembl chr 8:110,400,681...110,459,323

G

kelch-like family member 29

increases expression

chrysene results in increased expression of KLHL29 mRNA

NCBI chr 6:28,086,489...28,390,647
Ensembl chr 6:28,086,489...28,390,647

G

kelch-like family member 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL5 mRNA

NCBI chr14:43,144,254...43,206,192
Ensembl chr14:43,144,257...43,184,238

G

kelch-like family member 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL6 mRNA

NCBI chr11:80,970,917...81,010,593
Ensembl chr11:80,970,917...81,009,677

G

kallikrein 1-related peptidase C10

multiple interactions

alpha-naphthoflavone inhibits the reaction [chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]]; alpha-naphthoflavone inhibits the reaction [chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]]; chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]; chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]; Proadifen promotes the reaction [chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

lysine methyltransferase 2D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT2D mRNA

NCBI chr 7:129,980,744...130,022,088
Ensembl chr 7:129,962,887...130,020,325

G

lysine methyltransferase 5B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT5B mRNA

NCBI chr 1:201,000,444...201,049,819
Ensembl chr 1:201,000,444...201,049,819

G

keratin 13

increases expression

chrysene results in increased expression of KRT13 mRNA

NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084

G

keratin 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KRT15 mRNA

NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799

G

keratin 4

increases expression

chrysene results in increased expression of KRT4 mRNA

NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019

G

keratinocyte associated protein 2

decreases expression

chrysene results in decreased expression of KRTCAP2 mRNA

NCBI chr 2:174,654,409...174,658,405
Ensembl chr 2:174,654,219...174,658,405

G

laminin subunit alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LAMA1 mRNA

NCBI chr 9:107,692,770...107,816,847
Ensembl chr 9:107,692,770...107,817,478

G

laminin subunit alpha 5

increases expression

chrysene results in increased expression of LAMA5 mRNA

NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451

G

laminin subunit beta 1

increases expression

chrysene results in increased expression of LAMB1 mRNA

NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585

G

lysosomal protein transmembrane 4 alpha

decreases expression

chrysene results in decreased expression of LAPTM4A mRNA

NCBI chr 6:31,719,287...31,737,023
Ensembl chr 6:31,718,976...31,737,020

G

LARGE xylosyl- and glucuronyltransferase 2

increases expression

chrysene results in increased expression of LARGE2 mRNA

NCBI chr 3:78,334,627...78,347,167
Ensembl chr 3:78,336,056...78,342,184

G

La ribonucleoprotein 4B

increases expression

chrysene results in increased expression of LARP4B mRNA

NCBI chr17:61,138,663...61,217,423
Ensembl chr17:61,138,709...61,187,960

G

LIM and SH3 protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LASP1 mRNA

NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292

G

late cornified envelope 3E

increases expression

chrysene results in increased expression of LCE3B mRNA

NCBI chr 2:178,578,488...178,579,661
Ensembl chr 2:178,579,162...178,579,458

G

ligand dependent nuclear receptor corepressor-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LCORL mRNA

NCBI chr14:65,271,339...65,407,732
Ensembl chr14:65,271,135...65,404,174

G

left right determination factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEFTY1 mRNA

NCBI chr13:92,649,226...92,659,722
Ensembl chr13:92,656,323...92,659,720

G

leptin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEPR mRNA

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

galectin 1

increases expression

chrysene results in increased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

LHFPL tetraspan subfamily member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LHFPL3 mRNA

G

lipase A, lysosomal acid type

decreases expression

chrysene results in decreased expression of LIPA mRNA

NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633

G

loricrin cornified envelope precursor protein

increases expression

chrysene results in increased expression of LORICRIN mRNA

NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807

G

lipin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

leucine rich repeat containing 45

increases expression

chrysene results in increased expression of LRRC45 mRNA

NCBI chr10:105,994,468...106,002,425
Ensembl chr10:105,993,087...106,002,424

G

leucine rich repeat containing 75B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRRC75B mRNA

NCBI chr20:13,100,302...13,106,503
Ensembl chr20:13,100,302...13,106,503

G

leucine rich repeat containing 8 VRAC subunit B

decreases expression

chrysene results in decreased expression of LRRC8B mRNA

NCBI chr14:4,350,462...4,416,336
Ensembl chr14:4,354,508...4,416,311

G

leucine-rich repeat kinase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LRRK1 mRNA

NCBI chr 1:119,844,360...119,972,885
Ensembl chr 1:119,845,146...119,979,734

G

leucine rich repeat neuronal 4

increases expression

chrysene results in increased expression of LRRN4 mRNA

NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831

G

leucine-rich repeats and transmembrane domains 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRTM2 mRNA

NCBI chr 4:152,485,863...152,508,248
Ensembl chr 4:152,485,866...152,500,377

G

leukocyte specific transcript 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LST1 mRNA

NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997

G

leukotriene C4 synthase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LTC4S mRNA

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

LTV1 ribosome biogenesis factor

increases expression

chrysene results in increased expression of LTV1 mRNA

NCBI chr 1:7,565,673...7,578,398
Ensembl chr 1:7,565,669...7,578,563

G

lumican

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LUM mRNA

NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793

G

lymphocyte antigen 6 family member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LY6A mRNA

NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981

G

lymphatic vessel endothelial hyaluronan receptor 1

increases expression
multiple interactions

chrysene results in increased expression of LYVE1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LYVE1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309

G

leucine zipper tumor suppressor family member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LZTS3 mRNA

NCBI chr 3:117,850,286...117,861,132
Ensembl chr 3:117,851,702...117,860,081

G

membrane associated guanylate kinase, WW and PDZ domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGI3 mRNA

NCBI chr 2:191,514,726...191,717,048
Ensembl chr 2:191,518,506...191,716,735

G

magnesium transporter 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGT1 mRNA

NCBI chr X:71,038,489...71,079,704
Ensembl chr X:71,038,489...71,079,699

G

monoamine oxidase A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAOA mRNA

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA

NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698

G

macrophage receptor with collagenous structure

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MARCO mRNA

NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521

G

MARVEL domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MARVELD3 mRNA

NCBI chr19:37,908,727...37,923,420
Ensembl chr19:37,905,638...37,923,420

G

methionine adenosyltransferase 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAT1A mRNA

NCBI chr16:16,983,084...17,001,284
Ensembl chr16:16,983,022...17,001,274

G

methionine adenosyltransferase 2A

increases expression

chrysene results in increased expression of MAT2A mRNA

NCBI chr 4:104,489,877...104,495,447
Ensembl chr 4:104,488,466...104,495,493

G

membrane bound O-acyltransferase domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MBOAT2 mRNA

NCBI chr 6:41,471,135...41,597,599
Ensembl chr 6:41,471,161...41,593,485

G

melanoma cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MCAM mRNA

NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571

G

MDM2 proto-oncogene

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

MDM4 regulator of p53

decreases expression
multiple interactions

chrysene results in decreased expression of MDM4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDM4 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226

G

midasin AAA ATPase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDN1 mRNA

NCBI chr 5:47,055,435...47,190,426
Ensembl chr 5:47,055,447...47,186,332

G

mediator complex subunit 10

decreases expression

chrysene results in decreased expression of MED10 mRNA

NCBI chr 1:33,470,064...33,481,698
Ensembl chr 1:33,470,066...33,475,767

G

mediator complex subunit 21

decreases expression

chrysene results in decreased expression of MED21 mRNA

NCBI chr 4:179,560,509...179,583,811
Ensembl chr 4:179,560,579...179,567,548

G

mediator complex subunit 24

increases expression

chrysene results in increased expression of MED24 mRNA

NCBI chr10:83,664,609...83,702,315
Ensembl chr10:83,664,609...83,690,123

G

mediator complex subunit 28

decreases expression

chrysene results in decreased expression of MED28 mRNA

NCBI chr14:65,594,785...65,603,583
Ensembl chr14:65,594,647...65,603,583

G

mediator complex subunit 7

decreases expression

chrysene results in decreased expression of MED7 mRNA

NCBI chr10:30,842,330...30,857,873
Ensembl chr10:30,842,292...30,859,220

G

myocyte enhancer factor 2C

increases expression

chrysene results in increased expression of MEF2C mRNA

NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880

G

maternally expressed 3

increases expression

chrysene results in increased expression of MEG3 mRNA

NCBI chr 6:128,491,808...128,524,010

G

microfibril associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MFAP2 mRNA

NCBI chr 5:153,312,068...153,320,266
Ensembl chr 5:153,314,711...153,320,259

G

microfibril associated protein 4

increases expression
multiple interactions

chrysene results in increased expression of MFAP4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MFAP4 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

chrysene results in increased expression of MFSD2A mRNA

NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690

G

alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGAT2 mRNA

NCBI chr 6:87,656,360...87,658,849
Ensembl chr 6:87,656,349...87,658,177

G

monoglyceride lipase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGLL mRNA

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

O-6-methylguanine-DNA methyltransferase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MGMT mRNA

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

MIA SH3 domain containing

decreases expression

chrysene results in decreased expression of MIA mRNA

NCBI chr 1:82,473,677...82,476,378
Ensembl chr 1:82,473,678...82,475,370

G

MICAL-like 1

increases expression

chrysene results in increased expression of MICALL1 mRNA

NCBI chr 7:110,676,706...110,707,171
Ensembl chr 7:110,676,775...110,707,177

G

mitotic deacetylase associated SANT domain protein

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MIDEAS mRNA
chrysene results in decreased expression of MIDEAS mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:103,784,779...103,854,470
Ensembl chr 6:103,787,873...103,829,178

G

marker of proliferation Ki-67

multiple interactions

[benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with Benzo(a)pyrene co-treated with chrysene] results in increased expression of MKI67 protein; [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MKI67 mRNA

PMID:27858113 PMID:38237855

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

MTOR associated protein, LST8 homolog

increases expression

chrysene results in increased expression of MLST8 mRNA

NCBI chr10:13,498,377...13,504,128
Ensembl chr10:13,498,388...13,504,128

G

membrane magnesium transporter 1

decreases expression

chrysene results in decreased expression of MMGT1 mRNA

NCBI chr X:134,408,463...134,420,798
Ensembl chr X:134,408,466...134,420,729

G

matrix metallopeptidase 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MMP14 mRNA

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMP8 mRNA

NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520

G

multimerin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMRN2 mRNA

NCBI chr16:9,705,925...9,727,405
Ensembl chr16:9,705,892...9,727,405

G

mannose-P-dolichol utilization defect 1

decreases expression

chrysene results in decreased expression of MPDU1 mRNA

NCBI chr10:54,374,719...54,380,301
Ensembl chr10:54,374,725...54,380,447

G

macrophage expressed 1

decreases expression
multiple interactions

chrysene results in decreased expression of MPEG1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MPEG1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:209,452,176...209,456,692
Ensembl chr 1:209,452,133...209,458,855

G

MPV17 mitochondrial inner membrane protein like 2

decreases expression

chrysene results in decreased expression of MPV17L2 mRNA

NCBI chr16:18,680,106...18,684,212
Ensembl chr16:18,681,826...18,684,212

G

membrane spanning 4-domains A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MS4A1 mRNA

NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512

G

mesothelin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MSLN mRNA

NCBI chr10:14,771,946...14,781,382
Ensembl chr10:14,771,961...14,777,643

G

macrophage scavenger receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MSR1 mRNA

NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676

G

macrophage stimulating 1 receptor

increases expression

chrysene results in increased expression of MST1R mRNA

NCBI chr 8:108,596,100...108,611,441
Ensembl chr 8:108,597,299...108,612,455

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND4L mRNA

NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
Ensembl chr MT:9,870...10,166

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

metallothionein 1

increases expression

chrysene results in increased expression of MT1 mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

metallothionein 2A

increases expression

chrysene results in increased expression of MT2 mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mitochondrial fission regulator 1

decreases expression

chrysene results in decreased expression of MTFR1 mRNA

NCBI chr 2:101,678,331...101,713,547
Ensembl chr 2:101,679,265...101,713,544

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTHFD1L mRNA

NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905

G

myotubularin related protein 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTMR10 mRNA

NCBI chr 1:117,859,355...117,910,839
Ensembl chr 1:117,859,267...117,910,849

G

mucin 16, cell surface associated

increases expression

chrysene results in increased expression of MUC16 mRNA

NCBI chr 8:16,164,531...16,323,126

G

myeloid-associated differentiation marker

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MYADM mRNA

NCBI chr 1:65,864,180...65,874,701
Ensembl chr 1:65,864,173...65,874,035

G

myosin binding protein C1

increases expression

chrysene results in increased expression of MYBPC1 mRNA

NCBI chr 7:22,930,350...23,015,981
Ensembl chr 7:22,930,350...23,015,957

G

myosin heavy chain 1

increases expression

chrysene results in increased expression of MYH1 mRNA

NCBI chr10:51,885,913...51,909,699
Ensembl chr10:51,885,913...51,946,295

G

myosin heavy chain 4

increases expression

chrysene results in increased expression of MYH4 mRNA

NCBI chr10:51,923,149...51,946,297
Ensembl chr10:51,885,913...51,946,295

G

myosin light chain 6

increases expression

chrysene results in increased expression of MYL6 mRNA

NCBI chr 7:910,764...914,062
Ensembl chr 7:910,774...933,791

G

myosin light chain kinase

increases expression

chrysene results in increased expression of MYLK mRNA

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

myosin IG

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA

NCBI chr14:81,386,701...81,401,843
Ensembl chr14:81,386,701...81,401,843

G

myomesin 3

increases expression

chrysene results in increased expression of MYOM3 mRNA

NCBI chr 5:147,992,737...148,043,282
Ensembl chr 5:147,992,737...148,043,274

G

myozenin 1

increases expression

chrysene results in increased expression of MYOZ1 mRNA

NCBI chr15:3,644,333...3,651,584
Ensembl chr15:3,644,368...3,652,884

G

N-acetyltransferase 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NAT8 mRNA

NCBI chr 4:118,279,521...118,284,671
Ensembl chr 4:118,270,954...118,281,763

G

neurobeachin-like 1

decreases expression

chrysene results in decreased expression of NBEAL1 mRNA

NCBI chr 9:61,575,154...61,743,896
Ensembl chr 9:61,575,356...61,736,750

G

non-SMC condensin I complex, subunit H

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NCAPH mRNA

NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180

G

nuclear cap binding protein subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP2 mRNA

NCBI chr11:68,821,026...68,829,863
Ensembl chr11:68,817,740...68,851,885

G

nuclear cap binding subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP3 mRNA

NCBI chr10:57,665,716...57,695,432
Ensembl chr10:57,665,716...57,695,432

G

nuclear receptor coactivator 3

increases expression

chrysene results in increased expression of NCOA3 mRNA

NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594

G

NDC80 kinetochore complex component

decreases expression

chrysene results in decreased expression of NDC80 mRNA

NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924

G

NADH:ubiquinone oxidoreductase subunit B6

decreases expression

chrysene results in decreased expression of NDUFB6 mRNA

NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181

G

nuclear paraspeckle assembly transcript 1

increases expression

chrysene results in increased expression of NEAT1 mRNA

NCBI chr 1:203,129,229...203,140,014

G

nebulin

increases expression

chrysene results in increased expression of NEB mRNA

NCBI chr 3:36,613,677...36,811,618
Ensembl chr 3:36,613,716...36,811,574

G

nectin cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PVRL1 mRNA

NCBI chr 8:44,101,776...44,164,863
Ensembl chr 8:44,101,776...44,189,787

G

neuraminidase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NEU2 mRNA

NCBI chr 9:88,218,494...88,267,356
Ensembl chr 9:88,249,135...88,267,355

G

nexilin (F actin binding protein)

increases expression

chrysene results in increased expression of NEXN mRNA

NCBI chr 2:241,186,783...241,218,315
Ensembl chr 2:241,186,790...241,218,342

G

nuclear factor of activated T-cells 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFATC1 mRNA

NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028

G

nuclear factor, erythroid 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NFE2 mRNA

NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108

G

nuclear factor, interleukin 3 regulated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

NFKB inhibitor alpha

decreases expression

chrysene results in decreased expression of NFKBIA mRNA

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nerve growth factor receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFRSF10B mRNA

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

NHL repeat containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NHLRC2 mRNA

NCBI chr 1:255,589,743...255,648,904
Ensembl chr 1:255,589,742...255,651,408

G

NHS-like 1

increases expression

chrysene results in increased expression of NHSL1 mRNA

NCBI chr 1:12,956,525...13,188,580
Ensembl chr 1:12,956,021...13,187,547

G

natural killer cell triggering receptor

decreases expression
multiple interactions

chrysene results in decreased expression of NKTR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NKTR mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:121,380,010...121,420,495
Ensembl chr 8:121,382,436...121,418,314

G

NOC2-like nucleolar associated transcriptional repressor

increases expression

chrysene results in increased expression of NOC2L mRNA

NCBI chr 5:166,820,150...166,831,949
Ensembl chr 5:166,820,161...166,831,949

G

non-POU domain containing, octamer-binding

increases expression

chrysene results in increased expression of NONO mRNA

NCBI chr X:66,554,131...66,571,992
Ensembl chr X:66,554,098...66,571,952

G

NOP2 nucleolar protein

increases expression

chrysene results in increased expression of NOP2 mRNA

NCBI chr 4:157,932,731...157,944,462
Ensembl chr 4:157,932,716...157,944,459

G

notch receptor 1

decreases expression
multiple interactions

chrysene results in decreased expression of NOTCH1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NOTCH1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

NADPH oxidase activator 1

decreases expression

chrysene results in decreased expression of NOXA1 mRNA

NCBI chr 3:7,895,488...7,907,011
Ensembl chr 3:7,895,488...7,905,967

G

nephrocystin 1

decreases expression
multiple interactions

chrysene results in decreased expression of NPHP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NPHP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234

G

nucleophosmin 1

increases expression

chrysene results in increased expression of NPM1 mRNA

NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
Ensembl chr X:17,739,941...17,751,645

G

natriuretic peptide receptor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPR3 mRNA

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955

G

neuropeptide Y receptor Y1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA

NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759

G

NAD(P)H quinone dehydrogenase 1

increases activity

chrysene results in increased activity of NQO1 protein

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D1 mRNA

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 1, group D, member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D2 mRNA

NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553

G

nuclear receptor binding protein 2

increases expression

chrysene results in increased expression of NRBP2 mRNA

NCBI chr 7:107,798,642...107,805,225
Ensembl chr 7:107,799,497...107,805,230

G

neuronal cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NRCAM mRNA

NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992

G

nuclear receptor binding SET domain protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NSD1 mRNA

NCBI chr17:9,311,963...9,426,373
Ensembl chr17:9,315,237...9,425,358

G

NSFL1 cofactor

increases expression

chrysene results in increased expression of NSFL1C mRNA

NCBI chr 3:139,978,306...140,002,876
Ensembl chr 3:139,978,301...140,002,870

G

5'-nucleotidase domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NT5DC2 mRNA

NCBI chr16:6,322,485...6,330,538
Ensembl chr16:6,322,236...6,330,537

G

netrin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NTN1 mRNA

NCBI chr10:52,899,933...53,098,591
Ensembl chr10:52,899,934...53,085,326

G

nuclear FMR1 interacting protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NUFIP2 mRNA

NCBI chr10:62,574,922...62,607,729
Ensembl chr10:62,574,882...62,600,346

G

nucleoporin 85

increases expression

chrysene results in increased expression of NUP85 mRNA

NCBI chr10:100,806,482...100,825,029
Ensembl chr10:100,806,437...100,825,043

G

nuclear RNA export factor 1

increases expression

chrysene results in increased expression of NXF1 mRNA

NCBI chr 1:205,655,442...205,668,637
Ensembl chr 1:205,655,375...205,668,636

G

nucleoredoxin

increases expression

chrysene results in increased expression of NXN mRNA

NCBI chr10:61,109,322...61,247,578
Ensembl chr10:61,110,020...61,248,251

G

neurexophilin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NXPH3 mRNA

NCBI chr10:80,456,283...80,459,949
Ensembl chr10:80,455,429...80,462,415

G

O-GlcNAcase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of OGA mRNA

NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359

G

purinergic receptor P2X 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of P2RX7 mRNA

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

proliferation-associated 2G4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PA2G4 mRNA

NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331

G

PABPN1 like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PABPN1L mRNA

NCBI chr19:50,669,965...50,673,409
Ensembl chr19:50,669,967...50,673,366

G

PAF1 homolog, Paf1/RNA polymerase II complex component

increases expression

chrysene results in increased expression of PAF1 mRNA

NCBI chr 1:83,683,654...83,689,233
Ensembl chr 1:83,668,813...83,689,237

G

phenylalanine hydroxylase

decreases expression

chrysene results in decreased expression of PAH mRNA

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

palmdelphin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PALMD mRNA

NCBI chr 2:204,889,526...204,941,355
Ensembl chr 2:204,889,533...204,941,519

G

poly(A) specific ribonuclease subunit PAN3

increases expression

chrysene results in increased expression of PAN3 mRNA

NCBI chr12:7,476,707...7,595,384
Ensembl chr12:7,476,697...7,599,204

G

pantothenate kinase 4

increases expression

chrysene results in increased expression of PANK4 mRNA

NCBI chr 5:165,525,340...165,542,139
Ensembl chr 5:165,525,402...165,542,135

G

poly (A) polymerase alpha

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PAPOLA mRNA

NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468

G

prostate androgen-regulated mucin-like protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PARM1 mRNA

NCBI chr14:16,468,309...16,577,339
Ensembl chr14:16,468,459...16,577,314

G

PDZ binding kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PBK mRNA

NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014

G

PBX homeobox 1

decreases expression
multiple interactions

chrysene results in decreased expression of PBX1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PBX1 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:80,278,766...80,588,563
Ensembl chr13:80,278,770...80,588,594

G

protocadherin 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PCDH17 mRNA

NCBI chr15:60,222,088...60,316,172
Ensembl chr15:60,222,004...60,313,999

G

protocadherin alpha subfamily C, 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHAC2 mRNA

Ensembl chr18:28,581,225...28,846,211

G

protocadherin gamma subfamily A, 9

decreases expression
multiple interactions

chrysene results in decreased expression of PCDHGA9 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHGA9 mRNA

PMID:26377693 PMID:27858113

NCBI chr18:29,564,614...29,667,865

G

Purkinje cell protein 2

increases expression

chrysene results in increased expression of PCP2 mRNA

NCBI chr12:1,681,659...1,683,899
Ensembl chr12:1,681,659...1,683,899

G

PDGFA associated protein 1

increases expression

chrysene results in increased expression of PDAP1 mRNA

NCBI chr12:9,470,652...9,480,880
Ensembl chr12:9,470,574...9,535,374

G

phosphodiesterase 4A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PDE4A mRNA

NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961

G

pyruvate dehydrogenase kinase 2

increases expression

chrysene results in increased expression of PDK2 mRNA

NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085

G

pyridoxal kinase

decreases expression

chrysene results in decreased expression of PDXK mRNA

NCBI chr20:10,210,276...10,232,314
Ensembl chr20:10,210,289...10,232,110

G

phosphatidylethanolamine binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PEBP1 mRNA

NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862

G

platelet and endothelial cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PECAM1 mRNA

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

period circadian regulator 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER1 mRNA

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER2 mRNA

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

period circadian regulator 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER3 mRNA

NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PFKFB3 mRNA

NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125

G

post-GPI attachment to proteins 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PGAP2 mRNA

NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114

G

PHD finger protein 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHF19 mRNA

NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405

G

PHD finger protein 20-like 1

decreases expression

chrysene results in decreased expression of PHF20L1 mRNA

NCBI chr 7:98,330,580...98,396,526
Ensembl chr 7:98,330,580...98,396,526

G

PHD finger protein 21A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PHF21A mRNA

NCBI chr 3:78,158,760...78,331,903
Ensembl chr 3:78,194,549...78,331,865

G

pleckstrin homology-like domain, family A, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLDA3 mRNA

NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335

G

PH domain and leucine rich repeat protein phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLPP1 mRNA

NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977

G

phytanoyl-CoA 2-hydroxylase interacting protein

increases expression

chrysene results in increased expression of PHYHIP mRNA

NCBI chr15:45,533,974...45,545,223
Ensembl chr15:45,533,974...45,545,221

G

piezo-type mechanosensitive ion channel component 1

increases expression

chrysene results in increased expression of PIEZO1 mRNA

NCBI chr19:50,544,580...50,606,812
Ensembl chr19:50,544,582...50,606,501

G

polymeric immunoglobulin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIGR mRNA

NCBI chr13:42,298,905...42,326,877
Ensembl chr13:42,298,914...42,326,875

G

Pim-1 proto-oncogene, serine/threonine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIM1 mRNA

NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174

G

PICALM interacting mitotic regulator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIMREG mRNA

NCBI chr10:56,669,603...56,674,540
Ensembl chr10:56,669,675...56,674,791

G

PIN2/TERF1 interacting, telomerase inhibitor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PINX1 mRNA

NCBI chr15:38,097,896...38,157,143
Ensembl chr15:38,097,886...38,157,140

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIP4P1 mRNA

NCBI chr15:24,146,854...24,150,739
Ensembl chr15:24,146,856...24,150,702

G

cAMP-dependent protein kinase inhibitor alpha

increases expression

chrysene results in increased expression of PKIA mRNA

NCBI chr 2:94,398,869...94,473,638
Ensembl chr 2:94,398,869...94,414,282

G

cAMP-dependent protein kinase inhibitor gamma

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKIG mRNA

NCBI chr 3:152,330,477...152,398,085
Ensembl chr 3:152,366,041...152,398,082

G

protein kinase N3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKN3 mRNA

NCBI chr 3:13,350,082...13,363,572
Ensembl chr 3:13,335,041...13,363,567

G

placenta associated 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLAC8 mRNA

NCBI chr14:9,052,601...9,074,264
Ensembl chr14:9,063,048...9,074,264

G

PLAG1 like zinc finger 2

increases expression

chrysene results in increased expression of PLAGL2 mRNA

NCBI chr 3:141,695,322...141,708,516
Ensembl chr 3:141,695,322...141,708,503

G

plasminogen activator, tissue type

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PLAT mRNA

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

phospholipase C beta 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCB1 mRNA

NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869

G

phospholipase C, delta 1

increases expression

chrysene results in increased expression of PLCD1 mRNA

NCBI chr 8:118,795,196...118,818,186
Ensembl chr 8:118,795,201...118,818,186

G

phospholipase C, delta 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCD4 mRNA

NCBI chr 9:76,115,523...76,158,602
Ensembl chr 9:76,117,168...76,142,453

G

phospholipase C, eta 2

increases expression

chrysene results in increased expression of PLCH2 mRNA

NCBI chr 5:165,544,209...165,613,769
Ensembl chr 5:165,544,200...165,602,356

G

pleckstrin homology and RhoGEF domain containing G6

increases expression

chrysene results in increased expression of PLEKHG6 mRNA

NCBI chr 4:158,163,443...158,182,628
Ensembl chr 4:158,162,969...158,182,271

G

pleckstrin homology, MyTH4 and FERM domain containing H3

increases expression

chrysene results in increased expression of PLEKHH3 mRNA

NCBI chr10:86,098,461...86,106,931
Ensembl chr10:86,098,469...86,106,880

G

polo-like kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

polo-like kinase 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK5 mRNA

NCBI chr 7:9,346,777...9,367,923
Ensembl chr 7:9,346,777...9,355,196

G

phospholipid phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PPAP2A mRNA

NCBI chr 2:44,439,002...44,500,430
Ensembl chr 2:44,438,994...44,501,268

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PMAIP1 mRNA

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

peripheral myelin protein 22

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PMP22 mRNA

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

pregnancy up-regulated nonubiquitous CaM kinase

increases expression

chrysene results in increased expression of PNCK mRNA

NCBI chr X:151,369,406...151,373,508
Ensembl chr X:151,369,410...151,373,446

G

PNMA family member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PNMA2 mRNA

NCBI chr15:41,111,942...41,119,649
Ensembl chr15:41,112,009...41,121,427

G

DNA polymerase delta interacting protein 3

increases expression

chrysene results in increased expression of POLDIP3 mRNA

NCBI chr 7:114,274,845...114,303,278
Ensembl chr 7:114,275,085...114,303,271

G

DNA polymerase kappa

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POLK mRNA

NCBI chr 2:27,822,228...27,882,331
Ensembl chr 2:27,822,679...27,882,313

G

proteasome maturation protein

decreases expression

chrysene results in decreased expression of POMP mRNA

NCBI chr12:7,162,098...7,174,737
Ensembl chr12:7,160,714...7,174,715

G

paraoxonase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PON2 mRNA

NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248

G

POU class 2 homeobox associating factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POU2AF1 mRNA

NCBI chr 8:51,521,813...51,548,819
Ensembl chr 8:51,474,015...51,548,819

G

PTPRF interacting protein alpha 3

increases expression

chrysene results in increased expression of PPFIA3 mRNA

NCBI chr 1:95,817,110...95,845,950
Ensembl chr 1:95,817,110...95,845,798

G

peptidylprolyl isomerase G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PPIG mRNA

NCBI chr 3:54,484,023...54,512,929
Ensembl chr 3:54,484,023...54,512,926

G

protein phosphatase, Mg2+/Mn2+ dependent, 1A

decreases expression

chrysene results in decreased expression of PPM1A mRNA

NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697

G

prickle planar cell polarity protein 3

increases expression

chrysene results in increased expression of PRICKLE3 mRNA

NCBI chr X:14,837,647...14,849,305
Ensembl chr X:14,837,650...14,848,218

G

protein kinase AMP-activated non-catalytic subunit gamma 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRKAG3 mRNA

NCBI chr 9:76,295,715...76,304,959
Ensembl chr 9:76,295,715...76,304,959

G

protein kinase C, epsilon

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRKCE mRNA

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

protein kinase C, iota

increases expression

chrysene results in increased expression of PRKCI mRNA

NCBI chr 2:112,321,919...112,382,305
Ensembl chr 2:112,321,929...112,382,352

G

proline and serine rich 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PROSER2 mRNA

NCBI chr17:72,151,961...72,187,524
Ensembl chr17:72,151,872...72,185,825

G

pre-mRNA processing factor 38B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF38B mRNA

NCBI chr 2:196,553,224...196,562,271
Ensembl chr 2:196,553,225...196,562,250

G

pre-mRNA processing factor 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF4B mRNA

NCBI chr17:29,985,343...30,020,285
Ensembl chr17:29,985,343...30,019,625

G

proline rich 7 (synaptic)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRR7 mRNA

NCBI chr17:9,164,375...9,173,669
Ensembl chr17:9,165,269...9,172,536

G

proline rich and Gla domain 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRRG3 mRNA

NCBI chr X:149,666,498...149,689,353
Ensembl chr X:149,670,257...149,677,373

G

serine protease 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS12 mRNA

NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126

G

serine protease 23

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

proteasome 26S subunit, non-ATPase 3

increases expression

chrysene results in increased expression of PSMD3 mRNA

NCBI chr10:83,643,473...83,655,620
Ensembl chr10:83,643,647...83,655,618

G

proline and serine rich coiled-coil 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PSRC1 mRNA

NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874

G

polypyrimidine tract binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTBP1 mRNA

NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397

G

prothymosin alpha

increases expression
multiple interactions

chrysene results in increased expression of PTMA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTMA mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333

G

protein tyrosine phosphatase, non-receptor type 5

decreases expression

chrysene results in decreased expression of PTPN5 mRNA

NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882

G

protein tyrosine phosphatase, receptor type, B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTPRB mRNA

NCBI chr 7:51,953,375...52,034,751
Ensembl chr 7:51,930,015...52,034,748

G

protein tyrosine phosphatase, receptor type, G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PTPRG mRNA

NCBI chr15:12,871,706...13,552,186
Ensembl chr15:12,871,721...13,554,094

G

protein tyrosine phosphatase, receptor type Z1

increases expression

chrysene results in increased expression of PTPRZ1 mRNA

NCBI chr 4:51,397,316...51,595,220
Ensembl chr 4:51,397,601...51,595,218

G

RAB11 family interacting protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RAB11FIP1 mRNA

NCBI chr16:64,886,902...64,917,491
Ensembl chr16:64,884,676...64,917,491

G

RAB44, member RAS oncogene family

increases expression

chrysene results in increased expression of RAB44 mRNA

NCBI chr20:7,164,576...7,198,473
Ensembl chr20:7,164,720...7,198,468

G

Rab acceptor 1

decreases expression

chrysene results in decreased expression of RABAC1 mRNA

NCBI chr 1:80,564,029...80,567,164
Ensembl chr 1:80,564,033...80,567,163

G

Rab geranylgeranyltransferase subunit beta

decreases expression

chrysene results in decreased expression of RABGGTB mRNA

NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050

G

RAD51 recombinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAD51 mRNA

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

retinoic acid induced 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAI2 mRNA

NCBI chr X:32,948,656...33,011,222
Ensembl chr X:32,948,656...33,011,264

G

receptor activity modifying protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAMP3 mRNA

NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902

G

RASD family, member 2

increases expression
multiple interactions

chrysene results in increased expression of RASD2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASD2 mRNA

PMID:26377693 PMID:27858113

NCBI chr19:13,594,291...13,605,016
Ensembl chr19:13,594,291...13,605,016

G

RasGEF domain family, member 1C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGEF1C mRNA

NCBI chr10:34,227,483...34,293,676
Ensembl chr10:34,227,483...34,293,675

G

RAS guanyl releasing protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGRP3 mRNA

NCBI chr 6:19,895,361...19,993,945
Ensembl chr 6:19,895,390...19,958,578

G

RAS-like family 11 member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RASL11A mRNA

NCBI chr12:8,258,148...8,260,909
Ensembl chr12:8,258,159...8,262,576

G

Ras association domain family member 1

increases expression

chrysene results in increased expression of RASSF1 mRNA

NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164

G

Ras association domain family member 8

decreases expression

chrysene results in decreased expression of RASSF8 mRNA

NCBI chr 4:178,716,110...178,798,042
Ensembl chr 4:178,719,992...178,796,690

G

RNA binding motif protein 25

increases expression

chrysene results in increased expression of RBM25 mRNA

NCBI chr 6:103,271,775...103,319,090
Ensembl chr 6:103,271,801...103,317,854

G

RNA binding motif protein 39

increases expression

chrysene results in increased expression of RBM39 mRNA

NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213

G

RNA binding motif protein 6

increases expression

chrysene results in increased expression of RBM6 mRNA

NCBI chr 8:108,452,687...108,552,783
Ensembl chr 8:108,452,687...108,552,771

G

retinol binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RBP1 mRNA

NCBI chr 8:99,025,218...99,046,740
Ensembl chr 8:99,025,206...99,046,743

G

receptor accessory protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP1 mRNA

NCBI chr 4:103,746,004...103,862,347
Ensembl chr 4:103,745,633...103,862,338

G

receptor accessory protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP2 mRNA

NCBI chr18:26,438,130...26,447,165
Ensembl chr18:26,438,346...26,447,161

G

REV1, DNA directed polymerase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REV1 mRNA

NCBI chr 9:40,278,100...40,351,764
Ensembl chr 9:40,278,101...40,351,576

G

REX4 homolog, 3'-5' exonuclease

increases expression

chrysene results in increased expression of REXO4 mRNA

NCBI chr 3:10,280,654...10,291,003
Ensembl chr 3:10,280,654...10,290,996

G

regulator of G-protein signaling 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RGS12 mRNA

NCBI chr14:75,715,925...75,824,012
Ensembl chr14:75,715,934...75,794,596

G

regulator of G-protein signaling 7 binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RGS7BP mRNA

NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505

G

ras homolog family member B

decreases expression
multiple interactions

chrysene results in decreased expression of RHOB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RHOB mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

ras homolog family member C

increases expression

chrysene results in increased expression of RHOC mRNA

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

ras homolog family member T2

increases expression

chrysene results in increased expression of RHOT2 mRNA

NCBI chr10:14,858,954...14,864,751
Ensembl chr10:14,858,956...14,864,751

G

reproductive homeobox 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RHOX8 mRNA

NCBI chr X:116,584,742...116,588,365
Ensembl chr X:116,584,582...116,588,365

G

ripply transcriptional repressor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RIPPLY3 mRNA

NCBI chr11:33,648,471...33,656,587
Ensembl chr11:33,648,486...33,656,584

G

ribonuclease A family member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNASE10 mRNA

NCBI chr15:24,226,687...24,229,149
Ensembl chr15:24,226,691...24,228,561

G

ribonuclease H2, subunit B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNASEH2B mRNA

NCBI chr15:36,541,200...36,592,016
Ensembl chr15:36,541,218...36,584,118

G

ring finger protein 144A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNF144A mRNA

NCBI chr 6:42,899,767...43,019,769
Ensembl chr 6:42,903,174...43,020,012

G

ring finger protein 169

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNF169 mRNA

NCBI chr 1:154,250,462...154,311,867
Ensembl chr 1:154,254,473...154,311,653

G

ring finger protein 20

increases expression

chrysene results in increased expression of RNF20 mRNA

NCBI chr 5:63,976,063...64,001,754
Ensembl chr 5:63,976,045...64,001,754

G

ring finger protein 43

increases expression

chrysene results in increased expression of RNF43 mRNA

NCBI chr10:72,461,508...72,537,301
Ensembl chr10:72,464,348...72,536,977

G

roundabout guidance receptor 1

decreases expression

chrysene results in decreased expression of ROBO1 mRNA

NCBI chr11:10,580,863...11,621,675
Ensembl chr11:10,580,908...11,620,203

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ROCK2 mRNA

NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031

G

RAR-related orphan receptor C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RORC mRNA

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

RNA polymerase II associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPAP2 mRNA

NCBI chr14:2,109,044...2,187,343
Ensembl chr14:2,109,053...2,187,350

G

ribosomal protein S27-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPS27L mRNA

NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418
Ensembl chr12:67,562,483...67,567,418
Ensembl chr 2:67,562,483...67,567,418

G

ribonucleotide reductase catalytic subunit M1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM1 mRNA

NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM2 mRNA

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

ribosomal RNA processing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RRP1 mRNA

NCBI chr20:10,260,892...10,272,141
Ensembl chr20:10,260,870...10,272,144

G

retinoschisin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RS1 mRNA

NCBI chr X:33,962,440...33,992,203
Ensembl chr X:33,963,657...33,992,115

G

arginine and serine rich protein 1

increases expression

chrysene results in increased expression of RSRP1 mRNA

NCBI chr 5:147,147,774...147,151,523
Ensembl chr 5:147,147,784...147,151,523

G

RT1 class II, locus DOa

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OA mRNA

NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577

G

RT1 class II, locus DOb

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OB mRNA

NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667

G

reticulon 3

decreases expression

chrysene results in decreased expression of RTN3 mRNA

NCBI chr 1:204,612,675...204,669,212
Ensembl chr 1:204,612,675...204,669,275

G

receptor (chemosensory) transporter protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RTP3 mRNA

NCBI chr 8:110,970,154...110,975,000
Ensembl chr 8:110,970,160...110,974,699

G

receptor (chemosensory) transporter protein 4

decreases expression

chrysene results in decreased expression of RTP4 mRNA

NCBI chr11:77,237,341...77,249,194
Ensembl chr11:77,238,216...77,335,437

G

RUN and FYVE domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RUFY2 mRNA

NCBI chr20:25,626,958...25,658,157
Ensembl chr20:25,621,999...25,658,186

G

ryanodine receptor 1

increases expression

chrysene results in increased expression of RYR1 mRNA

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

S100 calcium binding protein A14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A14 mRNA

NCBI chr 2:176,008,395...176,010,423
Ensembl chr 2:176,008,395...176,010,423

G

S100 calcium binding protein A6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A6 mRNA

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

sphingosine-1-phosphate receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S1PR1 mRNA

NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681

G

SAC3 domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SAC3D1 mRNA

NCBI chr 1:203,414,184...203,416,563
Ensembl chr 1:203,414,187...203,416,604

G

scaffold attachment factor B2

increases expression

chrysene results in increased expression of SAFB2 mRNA

NCBI chr 9:1,395,852...1,417,010
Ensembl chr 9:1,387,107...1,417,038

G

suprabasin

increases expression

chrysene results in increased expression of SBSN mRNA

NCBI chr 1:85,978,970...86,006,034
Ensembl chr 1:86,001,567...86,006,034

G

stearoyl-CoA desaturase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

sodium voltage-gated channel beta subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SCN3B mRNA

NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868

G

SCY1 like pseudokinase 1

increases expression

chrysene results in increased expression of SCYL1 mRNA

NCBI chr 1:203,045,776...203,059,550
Ensembl chr 1:203,045,741...203,059,533

G

stromal cell derived factor 4

decreases expression
multiple interactions

chrysene results in decreased expression of SDF4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SDF4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:166,586,581...166,606,661
Ensembl chr 5:166,586,390...166,604,521

G

SEC61 translocon subunit beta

decreases expression

chrysene results in decreased expression of SEC61B mRNA

NCBI chr 5:61,773,594...61,781,804
Ensembl chr 5:61,773,594...61,781,804

G

selenoprotein S

decreases expression

chrysene results in decreased expression of SELENOS mRNA

NCBI chr 1:119,659,779...119,669,546
Ensembl chr 1:119,659,751...119,669,833

G

selectin L

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SELL mRNA

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

semaphorin 3C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SEMA3C mRNA

NCBI chr 4:17,583,212...17,747,234
Ensembl chr 4:17,583,212...17,746,534

G

septin 11

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN11 mRNA

NCBI chr14:14,844,759...14,990,856
Ensembl chr14:14,844,580...14,990,853

G

septin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN3 mRNA

NCBI chr 7:113,783,217...113,811,089
Ensembl chr 7:113,783,095...113,811,087

G

stress-associated endoplasmic reticulum protein family member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERP2 mRNA

NCBI chr15:51,879,882...51,903,958
Ensembl chr15:51,879,877...51,904,785

G

serpin family B member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB10 mRNA

NCBI chr13:23,553,348...23,571,182
Ensembl chr13:23,553,430...23,571,182

G

serpin family B member 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB1A mRNA

NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102

G

serpin family B member 5

increases expression

chrysene results in increased expression of SERPINB5 mRNA

NCBI chr13:22,985,557...23,005,756
Ensembl chr13:22,985,557...23,005,756

G

serpin family E member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

SERTA domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SERTAD2 mRNA

NCBI chr14:94,733,637...94,838,200
Ensembl chr14:94,733,579...94,838,313

G

sestrin 2

decreases expression
multiple interactions

chrysene results in decreased expression of SESN2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SESN2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

SET domain containing 1B, histone lysine methyltransferase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SETD1B mRNA

NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934

G

SET domain containing 6, protein lysine methyltransferase

increases expression

chrysene results in increased expression of SETD6 mRNA

NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453

G

SFI1 centrin binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFI1 mRNA

NCBI chr14:77,990,965...78,048,352
Ensembl chr14:77,990,965...78,048,255

G

SWI5-dependent homologous recombination repair protein 1

increases expression

chrysene results in increased expression of SFR1 mRNA

NCBI chr 1:246,619,235...246,623,250
Ensembl chr 1:246,597,044...246,623,250

G

secreted frizzled-related protein 2

increases expression

chrysene results in increased expression of SFRP2 mRNA

NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063

G

sideroflexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFXN2 mRNA

NCBI chr 1:245,447,014...245,459,312
Ensembl chr 1:245,447,015...245,468,411
Ensembl chr 1:245,447,015...245,468,411

G

sphingomyelin synthase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SGMS1 mRNA

NCBI chr 1:229,996,673...230,259,591
Ensembl chr 1:229,998,119...230,259,603

G

SH3 domain binding glutamate-rich protein

increases expression

chrysene results in increased expression of SH3BGR mRNA